Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KetCRPS-2 esketamine for long-term pain modulation in CRPS
2024-511877-31-00Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in complex regional pain syndrome (CRPS) (2 arms), sponsored by Erasmus MC. Primary endpoint: Pain intensity (current and average last 24 hours) by Numerical Rating Scale (NRS) at T0, T3, T4. Started Apr 2024; status: completed.
02
Drugs
esketamine
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on 2024-511877-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511877-31-00.